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Abstract
Background: Toll-like receptor (TLR) 2 is a component of the innate immune system and senses specific pathogen
associated molecular patterns (PAMPs) of both microbial and viral origin. Cell activation via TLR2 and other pattern
recognition receptors (PRRs) contributes to sepsis pathology and chronic inflammation both relying on
overamplification of an immune response. Intracellular antibodies expressed and retained inside the endoplasmatic
reticulum (ER-intrabodies) are applied to block translocation of secreted and cell surface molecules from the ER to
the cell surface resulting in functional inhibition of the target protein. Here we describe generation and application
of a functional anti-TLR2 ER intrabody (aT2ib) which was generated from an antagonistic monoclonal antibody
(mAb) towards human and murine TLR2 (T2.5) to inhibit the function of TLR2. aT2ib is a scFv fragment comprising
the variable domain of the heavy chain and the variable domain of the light chain of mAb T2.5 linked together by
a synthetic (Gly4Ser)3 amino acid sequence.
Results: Coexpression of aT2ib and mouse TLR2 in HEK293 cells led to efficient retention and accumulation of
TLR2 inside the ER compartment. Co-immunoprecipitation of human TLR2 with aT2ib indicated interaction of
aT2ib with its cognate antigen within cells. aT2ib inhibited NF-B driven reporter gene activation via TLR2 but not
through TLR3, TLR4, or TLR9 if coexpressed in HEK293 cells. Co-transfection of human TLR2 with increasing
amounts of the expression plasmid encoding aT2ib into HEK293 cells demonstrated high efficiency of the TLR2-
aT2ib interaction. The aT2ib open reading frame was integrated into an adenoviral cosmid vector for production
of recombinant adenovirus (AdV)-aT2ib. Transduction with AdVaT2ib specifically inhibited TLR2 surface expression
of murine RAW264.7 and primary macrophages derived from bone marrow (BMM). Furthermore, TLR2 activation
dependent TNFa mRNA accumulation, as well as TNFa translation and release by macrophages were largely
abrogated upon transduction of aT2ib. aT2ib was expressed in BMM and splenocytes over 6 days upon systemic
infection with AdVaT2ib. Systemic transduction applying AdVaT2ib rendered immune cells largely non-responsive
to tripalmitoyl-peptide challenge. Our results show persistent paralysis of TLR2 activity and thus inhibition of
immune activation.
Conclusion: The generated anti-TLR2 scFv intrabody inhibits specifically and very efficiently TLR2 ligand-driven cell
activation in vitro and ex vivo. This indicates a therapeutic potential of aT2ib in microbial or viral infections.
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Background
Among pattern recognition receptors (PRRs), toll-like
receptors (TLRs) are prominent as cellular sensors of
extracellularly encountered whole microbes or viruses,
or pathogen associated molecular patterns (PAMPs) [1].
Infection of hosts is associated with release of immune-
stimulatory PAMPs such as LPS upon Gram-negative
bacterial infection or lipoproteins and DNA upon vir-
tually any bacterial infection [2]. Systemic presence of
PAMPs at high concentrations and subsequent overam-
plification of immune responses through TLRs is recog-
nized as a major cause of sepsis for which high serum
concentrations of pro-inflammatory mediators such as
nitrogen monoxide and TNFa, as well as consequent
hypotension and disseminated coagulation are character-
istic. Sepsis frequently culminates upon multi-organ fail-
ure in fatal septic shock [3]. Chronic inflammation for
which persisting infection is viewed as one major trigger
might be maintained through PRR activation [4]. Target-
ing of PRRs such as CD14, TLR4, and TLR2 in models
of acute infection within which deliberate short term
antagonism is achieved by systemic application of neu-
tralizing mAbs has been shown to effectively inhibit
unwanted immune responses [5-7]. However, strategies
aiming at sustainable PRR antagonism have not yet been
brought forward.
As opposed to blockade of the ligand binding domain
of PRRs, inhibition of intracellular translocation of TLRs
from the endoplasmatic reticulum (ER) to the cell sur-
face or endosomal compartment would require a cyto-
plasmic entry to inhibit TLR function and rely on an
alternative strategy. Since intracellular antibodies (intra-
bodies) can be targeted to specific subcellular compart-
ments upon fusion to specific signal peptides (nucleus,
ER, mitochondria) or expressed inside the cytoplasm,
they might be helpful for targeting PRRs. Inside the sub-
cellular compartment the intrabody binds its cognate
target [8-10]. Thereby intrabodies might supplement
knock-down approaches such as antisense RNA or
RNAi/siRNA/shRNA application potentially inducing
off-target effects [11,12]. Major advantages of intrabo-
dies include high specificity, substantial length of active
half-life, opportunity of targeting protein domains or
epitopes, as well as inhibition of post-translational modi-
fication. An intrinsic prerequisite of the intrabody tech-
nique is availability of a mAb against a specific target
protein. If this need is met, cloning of the two DNA
sequences encoding the variable domains of the specific
mAb allows construction of a single chain Fv intrabody
construct fused to specific signal peptides for targeting
of specific subcellular compartments.
Intrabodies residing within the ER due to an ER reten-
tion peptide fused to the C-terminus of the respective
intrabody, have been shown to efficiently block trans-
location of otherwise secreted or cell surface bound mole-
cules to the cell surface [13]. ER intrabodies have been
applied successfully for inactivation of oncogenic receptors
as well as inhibition of virus envelope proteins and virus-
receptor molecules expressed on the surface of host cells.
Recent reports provide examples for blockade of transloca-
tion from the ER to the cell surface of specific antigens
such as vascular endothelial growth factor receptors
(VEGFR) 2 and Tie2, the human immunodeficiency virus
(HIV) 1 coat protein gp120, as well as the HIV-1 corecep-
tor CC-chemokin-receptor (CCR) 5 [10,14-17]. In addition
several receptors of the immune system have been
knocked down with ER intrabodies (e.g. IL-1 receptor,
MHC I, CD147 and VCAM, [18-21]).
Specifically, ER intrabodies carrying C-terminally the
ER retention peptide KDEL or SEKDEL bind to ER
retention defective (ERD) 2 receptor localized at the
inner surface of the ER and at the same time recognize
their specific antigen. The ER intrabody-target protein
complex is recycled via the cis Golgi network apparatus
to the ER [22]. The intrabody-antigen complex retained
in the ER is then being degraded possibly inside the ER
[23] or by a cytoplasmic proteosome-dependent [24] or
proteosome-independent pathway [[25])]. Intrinsically,
ER intrabodies are folded correctly due to interaction
with molecular chaperones and the oxidizing environ-
ment of the ER, which favors intra-domain disulfide
bond formation [26].
Here we describe the generation and characterisation
of an anti-TLR2 scFv ER intrabody (aT2ib). aT2ib
binds intracellularly and specifically to TLR2 as shown
by co-immunoprecipitation as well as efficient retention
and accumulation of TLR2 inside the ER upon over-
expression of aT2ib. As a consequence, TLR2 surface
expression and TLR2-specific activation of murine
macrophages is inhibited in vitro and ex vivo. Our data
indicate a therapeutic potential of aT2ib since it sus-
tainably prevents TLR2-driven inflammatory immune
responses.
Results
aT2ib expression and functionality upon transient
overexpression in HEK293 cells
The sequence of the aT2ib expression construct was as
illustrated (Fig. 1A). CMV promoter driven aT2ib
expression in transfected HEK293 cells was detected by
immunoblot (Fig. 1B) and immunofluorescence (data
not shown). The apparent molecular weight of aT2ib
was approximately 30 kDa (Fig. 1B). In order to analyse
aT2ib function, NF-B driven reporter gene activity in
HEK293 cells overexpressing both mTLR2 and aT2ib
upon TLR2 specific challenge was determined.
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Transfection of aT2ib expression plasmid DNA effec-
tively inhibited TLR2 activity (Fig. 2A). In contrast, cel-
lular activation through either TLR4-MD-2, TLR3, or
TLR9 was not influenced by aT2ib coexpression (Fig.
2B-D). Another ER intrabody recognizing vascular
endothelial growth factor receptor (VEGFR/KDR) 2 did
not diminish TLR2 activation (Fig. 2A and data not
shown). In addition, an aT2ib dose-dependent inhibition
of TLR2 cell surface expression was observed (Fig. 2E).
Moreover, the control-intrabody aVR-ib hardly dimin-
ished TLR2 cell surface expression to a detectable extent
(Fig. 2E, right diagram).
Colocalization of aT2ib and TLR2 inside the ER
compartment and intracellular binding of aT2ib to TLR2
Fluorescent labeling revealed colocalization of aT2ib
with mTLR2 indicating complex formation of both
molecules (Fig. 3A, iv). The aT2ib-mTLR2 complex
resided within a lattice structure identical with the ER
compartment. This interpretation was supported by
costaining of the intrabody-TLR2 complex with the ER
resident marker calnexin (Fig. 3A, v). Overexpression of
aT2ib led to strong accumulation of TLR2 inside the
ER. This accumulation was not seen when TLR2 was
coexpressed with the unspecific control-intrabody (aVR-
ib, data not shown). Specific intracellular binding of
TLR2 and aT2ib was indicated further by co-immuno-
precipitation (Fig. 3B, second lane on the left). Lack of
immunoprecipitation of TLR2 with control intrabody
(Fig. 3B, first lane on the left) in lysates of HEK292 cells
expressing respective protein pairs demonstrated aT2ib
specificity for its cognate antigen.
Adenoviral aT2ib expression and effects in macrophages
To increase overexpression of aT2ib in macrophages
and mice, we constructed an adenoviral vector and gen-
erated AdVaT2ib particles. Myc-tag specific immuno-
blot analysis of lysates of RAW264.7 macrophages that
had been infected with AdVaT2ib or the control virus
AdVGFP 3 days before revealed an apparent size of ade-
novirally transduced aT2ib of approximately 30 kDa
(Fig. 4A). Adenovirus mediated aT2ib expression
resembled that of aT2ib expressed upon DNA plasmid
or DNA adenoviral cosmid transfection in respect to
resultant protein size (compare Fig. 1B and 4A). Next,
we analysed intrabody expression and bicistronically
expressed EGFP by immunofluorescence determination
through both, flow cytometry and microscopy. Both ade-
noviral constructs AdVGFP and AdVaT2ib transduced
RAW264.7 macrophages equally effectively (Fig. 4B to
4D). Challenge of AdVGFP or AdVaT2ib infected
RAW264.7 macrophages with TLR2 or TLR4 agonists
for 4 h did not alter their EGFP-driven fluorescence
(data not shown). Infection rates of RAW264.7
Figure 1 Human/murine TLR2-cross-reactive intrabody
assembly and expression. A, Primary sequence of aT2ib. Shown
are the coding (lower lane) and amino acid sequence (upper lane)
of aT2ib including the ER signal peptide, the myc epitope and the
ER retention sequence. The complementary-determining regions
(CDR1-CDR3) of the variable domains of the heavy and light chain
are printed in bold. The synthetic linker (shown in bold italic letters)
localized between the VH and VL domains was introduced by
assembly PCR (###, stop codon). B, Transient expression of the
aT2ib in HEK293 cells. Comparative immunoblot analysis of aT2ib
and AdVaT2ib cosmid clones 3 and 7 (/3,/7) expression in
transiently transfected HEK293 cells. As positive controls, samples of
E. coli periplasmic fraction of anti-VEGFR-2 scFv A7 (E. coli aVR-ab,
left lane) and anti-VEGFR-2 intrabody scFv A7, aVR-ib (lane at the
right side) transfected cells were applied. As negative control,
HEK293 cells transfected with the vector pCMV/myc/ER without
intrabody insert (right lane,-) were applied.
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macrophages were in the 80% range as revealed by
EGFP and myc-tag specific ELISA of cell lysates (Fig. 4B
and data not shown). In order to analyse the effect of
aT2ib expression on cell surface TLR2 expression, we
performed flow cytometry of cells left uninfected and
those formerly infected either with AdVaT2ib or
AdVGFP. TLR2 cell surface expression was well detect-
able on non-infected HEK293 cells stable overexpressing
murine TLR2, as well as on murine RAW264.7 macro-
phages (Fig. 5A and Fig 5B, left panels). Furthermore,
adenovirally overexpressed EGFP had no substantial
impact on cell surface TLR2 expression by HEK293/
mTLR2 cells, RAW264.7 macrophages, as well as pri-
mary macrophages (Fig. 5A and 5B central pannel,
Fig. 5C, left pannel). However, neither both of the two
different cell lines, nor primary macrophages expressed
Figure 2 Specificity of aT2ib function upon ectopic mouse TLR2 expression. A-D, Assay of NF-B driven reporter gene activation in HEK293
cells transiently coexpressing mTLR2 (A), mTLR4-MD-2 (B), hTLR3 (C) or mTLR9 (D) and aT2ib (black columns) or aVR-ib (white columns) and
challenged as indicated (unstim, non challenged). (E) 3 × 104 human embryonic kidney (HEK) 293 cells per single well of a 6-well microtitre plate
transfected with DNA plasmid driving expression of N-terminally-Flag-tagged human TLR2 were cotransfected with graded amounts of TLR2
specific intrabody (aT2ib) or control intrabody (aVR-ib) expression plasmid (line blue, 1 μg; green, 2 μg; red, 5 μg; line orange, 5 μg aT2ib
expression plasmid, no primary antiserum; line purple, empty vector) to overexpress each of the two different intrabodies transiently. Upon 48 h
cells from each well were subjected to flow cytometrical analysis using Flag-specific primary antiserum and PE coupled secondary antibody.
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Figure 3 Subcellular colocalisation and co-immunoprecipitation of aT2ib and mouse/human TLR2 upon transfection . A,
Immunofluorescence analysis by laser scanning confocal microscopy of fixed and permeabilized HEK 293 cells overexpressing mouse TLR2 and
transiently transfected with aT2ib expression plasmid. i, Expression of aT2ib analysed using FITC labelled anti-myc antibody, ii, Expression of TLR2
visualized by polyclonal anti-mTLR2 serum and Cy5 labelled goat anti-rabbit antibody; iii, Expression of calnexin visualized by anti-calnexin
antibody and Cy3 conjugated goat anti-mouse antibody, iv, Overlay of i and ii, v, Overlay of i, ii, iii. B, 3 × 105 HEK293 cells on a culture plate of
9 cm in diameter were transiently transfected with 5 μg expression plasmid DNA (to overexpress Flag-tagged human TLR2 and/or a myc-tagged
intrabody (ib-myc) as indicated) plus 5 μg of empty vector where only one expression plasmid was used. Upon 48 h cells were incubated in 1
ml lysis buffer and either analysed by immunoblotting directly (WCL, 20 ml whole cell lysate) or upon immunoprecipitation (IP) using myc tag-
specific antiserum (amyc) and protein A/G beads (except for *-tagged lane illustrating application of beads only).
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surface TLR2 to a detectable degree given they had been
infected with AdVaT2ib before (Fig. 5A to 5C, right
pannels). Next we determined aT2ib specificity by com-
parative analysis of surface TLR4 expression. Both
HEK293 cells overexpressing a Flag-tagged mTLR4-MD-
2 complex as well as RAW264.7 macrophages displayed
significant TLR4-specific staining (Fig. 6A and 6B, left
pannels) which was reduced in HEK293 cells possibly
due to reduced mTLR4-MD-2 complex expression in
favor of expression of tranduced EGFP (Fig. 6A, middle
pannel). Notably, TLR4 expression was not different to
a significant extent on the cell surface of both cell lines
given they were infected with either AdVGFP or AdVa-
T2ib before (Fig. 6A and 6B middle and right pannels)
Figure 4 Expression of adenovirally transduced aT2ib in RAW264.7 macrophages. A, For myc-tag specific immunoblot analysis of
RAW264.7 cell lysate the aT2ib protein band was visualized by application of a mouse anti-myc antibody. Non infected (no inf.) and AdVGFP
infected cells were used as control. B, Transduction efficiency of RAW264.7 cells infected with AdVGFP or AdVaT2ib analysed by flow cytometry.
Portion of infected cells was determined by analysis of green fluorescence by flow cytometry after 3 days of infection (empty area, noninfected
cells; black area, cells infected as indicated). C, D, Immunofluorescence analysis by microscopy of permeabilized and fixed cells (i, Transmitted
light; ii, Expression of EGFP visualized by UV-light; iii, Analysis of myc expression using a secondary TRITC labelled antibody).
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indicating specificity of aT2ib for TLR2. Furthermore,
aT2ib did not interfere with expression of the macro-
phage marker CD11b on RAW264.7 cells (Fig. 6C).
Inhibition of TLR2 specific signal transduction through
aT2ib expression
Aiming at analysis of aT2ib effects on cell activation at
the mRNA level we challenged RAW264.7 macrophages
with TLR2 or TLR4 specific agonists upon specific ade-
noviral infection. Later, mRNA levels were determined
by RT PCR. Within the time period of 4 h Pam3CSK4
and LPS challenge induced increase of cellular accumu-
lation of both TNFa and IL-6 mRNA regardless of
whether cells were left uninfected or had been infected
with AdVGFP (Fig. 7A). Cells infected with AdVaT2ib
responded similarly if challenged with LPS. In sharp
Figure 5 Transduced aT2ib inhibits surface TLR2 expression by murine macrophages. A-C, Flow cytometry of cell surface TLR2 of HEK293
cells overexpressing mouse TLR2 (A), RAW264.7 cells (B, Black area, PE staining correlating with TLR2 expression; white area, PE staining mediated
by isotype control antibody; living infected cells were gated on GFP), and peritoneal macrophages (C) expressing aT2ib. Inset in left diagramm
represents viability of primary macrophages (ethidium monoazide staining detected in PE-Texas Red versus PE channels, double positive cells
excluded; grey line in main diagrams, no primary mAb, -1. Ab; black line in main diagrams, PE-labelled aTLR2 mAb T2.5).
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contrast, neither IL-6 mRNA, nor TNFa mRNA were
found in Pam3CSK4 challenged macrophages that
expressed aT2ib upon adenoviral infection (Fig. 7A).
Asking for TNFa induction on the protein level, we per-
formed intracellular flow cytometry of intrabody expres-
sing RAW264.7 cells upon gating on GFP positive cells.
As shown in Fig. 7B, aT2ib expression inhibited intra-
cellular TNFa accumulation whereas TLR4 specific acti-
vation induced through LPS challenge was not affected
in respect to TNFa production. Adenoviral infection as
such had no effect on constitutive or TLR ligand
induced TNFa expression since AdVGFP infected cells
produced as much of intracellular TNFa as non-infected
macrophages (Fig. 7B). Thus, release of TNFa depended
on TLR specific challenge. While noninfected cells
responded to TLR2 or TLR4 specific challenge by
releasing TNFa at substantial amounts which was true
to an almost equal degree for cells infected with
AdVGFP, cells that were infected with AdVaT2ib were
unable to respond to a TLR2 specific challenge
Figure 6 Transduced aT2ib does not interfere with surface TLR4/CD11b expression. A-C, Flow cytometry of TLR4 and CD11b cell surface
expression of aT2ib expressing HEK293/mTLR4-MD-2 cells (A) and RAW264.7 cells (B, C, Black areas, specific staining; white areas, unspecific
staining with isotype control mAbs). All viable infected GFP+ cells were analysed.
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accordingly as shown for RAW264.7 and peritoneal
macrophages (Fig. 7C).
Effectiveness of systemic aT2ib transduction
We proceeded with analysis of cells from systemically
aT2ib transduced mice. Therefore, mice were adeno-
virally infected by i. v. injection of virus particles. 6 days
after infection viable splenocytes were analysed for
expression of bicistronically expressed EGFP by flow
cytometry (Fig. 8A). Whereas splenocytes from non-
infected mice were devoid of EGFP expression, mice
infected with control virus or virus driving aT2ib
expression expressed EGFP to well detectable degrees in
their splenocytes (Fig. 8A). Next we analysed CD11b+
peritoneal wash out cells from mice that had been ade-
novirally infected either i. v. or i. p. upon thioglycolate
injection 3 days earlier for EGFP expression. While peri-
toneal macrophages from mice that had not been
infected expressed no detectable EGFP, those of i. v.
infected mice contained EGFP+ cells. In contrast, in
those mice that had been infected i. p. the entirety of
the peritoneal macrophage population displayed
increased EGFP expression as compared to cells from
control mice (Fig. 8B, right panels). Consequently, peri-
toneal macrophages from mice formerly infected i. p.
with AdVaT2ib but not from AdVGFP or non-infected
mice were impaired in their ability to respond to low
dose TLR2 agonist challenge while they were fully
responsive to control stimulant (LPS, Fig. 8C). Similarly,
splenocytes that descended from mice that had formerly
been infected with AdVaT2ib but not from those
infected with AdVGFP displayed diminished responsive-
ness to TLR2-specific but not to TLR7-specific challenge
(Fig. 8D).
Discussion
Means for prevention of excessive inflammatory
immune actions are of substantial medical interest [2].
A major trigger of inflammation is infection, which is
sensed through pattern recognition receptors (PRRs) by
the host. Among signal transducing PRRs are TLRs,
which as type I receptors mediate specific signals from
the extracellular milieu into the cytoplasm [27]. Cellular
PRRs such as cell surface expressed CD14, TLR4 or
TLR2 have been blocked by application of soluble
antagonists carried by the serum. However, antagonism
of extracellular domains is only transient due to turn-
over of surface receptors and limited half-time of serum
contents. Treatment of long lasting or chronic inflam-
matory disease, however, might rely on sustained recep-
tor blockage. Likewise, blockage of intracellularly
localized PRRs would require an alternative approach.
Referring to this, intrabodies have accomplished both
persistent and intracellular blockade of receptors
Figure 7 Transduced aT2ib inhibits lipopeptide-but not LPS-
induced macrophage activation. TLR2 specific induction of
cytokine mRNA accumulation and protein production. RAW264.7
macrophages were challenged with 100 ng/ml Pam3CSK4 or 100
ng/ml LPS for 4 h at room temperature. A, Cytokine mRNA
accumulation in RAW264.7 macrophages was analysed upon RNA
isolation and cDNA synthesis. Specific PCR amplificates were
analysed semi-quantitatively (HPRT, hypoxanthine guanine
phophoribosyl transferase). B, RAW264.7 macrophages were fixed/
permeabilized and the TNFa release inhibited during stimulation.
Intracellular cytokine was analysed by flow cytometry (black areas,
specific staining; white areas, unspecific staining with isotype control
mAb). All viable infected GFP+ cells were analysed. C, Analysis of
cytokine release to cell supernatant by ELISA (white columns, non
infected; grey columns, AdVGFP infected; black columns, AdVaT2ib
infected). Results of four independent experiments (p < 0.001).
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Figure 8 Effective TLR2 inhibition through aT2ib-adenovirus infection in vivo. A-D, Mice were infected 6 d by intravenous (i. v.) or
intraperitoneal (i. p.) injection (3 d after thioglycolate injection i. p. was performed) of 1 × 109 pfu of either AdVaT2ib or AdVGFP. A, Splenocytes
were isolated from i. v. infected mice and stained with EMA and a CD11b specific antibody. Viable CD11b+ splenocytes were analysed for EGFP
expression by flow cytometry. As control splenocytes from non-infected mice were applied. B, Peritoneal wash out cells were drawn 6 d upon
adenoviral infection as indicated or from non-infected mice (control). Cells that were adherent after 2 h of cell culturing were stained with EMA
and analysed for EGFP expression. C, Peritoneal macrophages from mice infected with adenoviruses i. p. (white column, AdVGFP; black column,
AdVaT2ib) or from a non-infected TLR2-/- mouse (grey column) were challenged as indicated (none, non challenged) for 24 h after which
supernatants were sampled for cytokine content by ELISA (one result of two similar results out of two independent experiments, n = 2 per
group). D, Splenocytes from mice infected i. v. (white column, AdVGFP; black column, AdVaT2ib) were challenged for 24 h upon which
supernatant cytokine concentration was determined by ELISA (representative result of one out of two independent experiments, n = 4 per
group; n.d., not detected).
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involved in cell cycle progression or cell growth [10].
Therefore, we generated an ER-bound intrabody towards
TLR2 to evaluate its propensity for TLR2 blockade by
TLR2 arrestment in the ER. aT2ib was derived from an
antagonistic mAb towards both human and murine
TLR2 [6] and inhibited translocation of TLR2 to the cell
surface and TLR2 specific signal transduction both
in vitro and ex vivo.
The variable domains of T2.5 were fused via a peptide
linker and linked at the construct’s C-terminus to the
myc epitope followed by the ER retention peptide to a
scFv-fragment named aT2ib (Fig. 1A). aT2ib expression
was normal as compared to expression levels of pre-
viously generated intrabodies. Having an apparent size
of 30 kDa, aT2ib specifically inhibited TLR2 driven cell
activation since aT2ib effectiveness depended on TLR2
agonist dose and aT2ib did not inhibit activity of other
TLRs such as TLR3, TLR4 or TLR9. Notably, aT2ib did
not only inhibit cell surface expression and function of
murine TLR2, but also of ectopically expressed human
TLR2 (data not shown). Furthermore, a control intra-
body towards VEGFR2 did not interfere with activity of
any of the TLRs tested. aT2ib dose dependently inhib-
ited TLR2 cell surface expression whereas the transfec-
tion of a control intrabody (aVR-ib) expression plasmid
only marginally affected TLR2 cell surface expression.
aT2ib-driven inhibition was due to retention and
accumulation of the formed intrabody-TLR2 complex
inside the ER mediated by the ER retention sequence.
We showed colocalisation of TLR2 and aT2ib inside the
ER compartment upon synchronous staining with the
ER-resident marker calnexin as well as specific binding
of aT2ib to TLR2 by co-immunoprecipitation.
Aiming at effective transduction of murine macro-
phages we subcloned the aT2ib expression cassette into
an adenoviral vector which drove bicistronic EGFP
expression aside of aT2ib expression. Infection rates of
RAW264.7 macrophages were in the 80% range as
revealed by EGFP. Human macrophages specifically
human alveolar macrophages have been reported to
express low levels of CAR [28]. Nevertheless other
authors used also adenoviral vectors to study biological
effects in RAW 264.7 macrophages or peritoneal mouse
macrophages [29,30]. Recently it was shown that the
scavenger receptor A is responsible for uptake of adeno-
virus type 5 in J774 macrophages [31]. The exact
mechanism of the entry of recombinant adenovirus in
RAW 264.7 macrophages has not yet been studied.
Since the RAW 264.7 macrophages also express the sca-
venger receptor A, entry of the adenovirus might be
mediated by it. We suggest that it might be possible
that the efficient transduction could also be due to
macropinocytosis or phagocytosis triggered by the
recombinant adenovirus [32].
The size of aT2ib expressed upon AdVaT2ib infec-
tion was similar as compared to aT2ib expression which
was driven by transfected plasmid or cosmid. Notable,
AdVaT2ib infection reduced surface TLR2 expression
to almost baseline levels. Peritoneal macrophages
infected ex vivo by adenovirus to express control protein
expressed TLR2 at their surface to similar extent com-
pared to non-infected macrophages. However, AdVa-
T2ib infection resulted in abrogation of TLR2 cell
surface expression. Lack of interference of adenovirally
transduced aT2ib with surface TLR4 expression empha-
sized TLR2 specificity (Fig. 6).
Inhibitory effects of aT2ib extended to TLR2 induced
signal transduction since TLR2 specific induction of gene
activities was ablated in addition to diminished surface
TLR2 expression. In contrast, macrophages infected with
AdVaT2ib did increase inflammatory cytokine mRNA
accumulation upon LPS challenge (Fig. 7). At the same
time house keeping gene expression was not impaired.
Namely, both intracellular TNFa accumulation and cel-
lular release of TNFa upon TLR2-specific challenge were
at background level if aT2ib was expressed and in both
cases TLR4 specific cellular challenge was unimpaired.
These findings indicated both high effectiveness, as well
as high specificity of TLR2 retention in the ER.
To translate results of our analyses in vitro to the sys-
temic level, we infected naive mice with AdVaT2ib by i.
v. injection, as well as mice that had been thioglycolate
challenged 3 days earlier by i. p. injection of the adeno-
virus. 6 d after infection EGFP expression as an indica-
tion of aT2ib expression was evident upon infection i.v.
in splenocytes regardless of whether mice had been
infected with AdVaT2ib or AdVGFP. Even peritoneal
washout cells expressed EGFP to a detectable degree
regardless of whether mice had been transduced by
infection through the i. v. or the i. p. route before. Con-
sequently, those macrophages that originated from mice
that had been infected with AdVaT2ib were refractory
of responsiveness specifically to TLR2 specific challenge
in vitro similar to cells from uninfected TLR2-/- mice.
To our knowledge these data are first to show that
intracellular arrestment of a TLR by an ER intrabody
inhibits specific TLR activity. The specificity of mAbs
might be an advantage outweighing potentially compet-
ing approaches such as application of agents that inter-
fere with gene activation at the mRNA level [33].
Whether other vectors might accommodate the aT2ib
encoding nucleic acid more appropriately remains an
open question [34]. New approaches including transcrip-
tional and transductional targeting are promising in this
context [35,36]. Yet, our data clearly indicate highly
effective function of aT2ib that extends from nearly
abolished TLR2 cell surface expression to low cytokine
release from cells upon confrontation with TLR2
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agonists. Consequently, 6 d after initiation of systemic
adenoviral transduction immune cells were resistant to
TLR2 specific challenge. Further analysis will determine
the time frame of aT2ib activity from adenoviral infec-
tion on. Intrabody mediated PRR blockade as compared
to regular mAb mediated PRR blockage might not only
constitute an exclusive way to target intracellularly loca-
lized receptors using mAbs but also be advantageous for
blockade of those PRRs a possibly minor portion of
which is expressed superficially such as TLR2. An
obvious field of anti-TLR intrabody application might be
chronic inflammatory diseases such as inflammatory
bowel disease, asthma, or arthritis because it might call
for sustained anti-inflammatory action. TLRs have been
implicated as initial signal transmitters under such clini-
cal conditions [2,4,37]. A future perspective is the eva-
luation of the efficacy of aT2ib in mouse models of
chronic infections. Furthermore the intrabody strategy
might be used to block TLR2 specific TNFa secretion
of myeloid cells induced by factors secreted from
tumour cells promoting metastasis [38].
Conclusion
We generated and characterised an anti-TLR2 ER intra-
body that inhibits specifically and very efficiently macro-
phage surface TLR2 expression and TLR2-driven cell
activation in vitro and ex vivo. This indicates a therapeu-
tic potential of aT2ib for treatment of TLR2-driven
chronic inflammatory disease.
Methods
1. Cells and mice
Murine RAW264.7 macrophages were obtained from
the German strain collection (DSMZ, Braunschweig,
Germany), Human embryonic kidney (HEK293)/murine
(m)TLR2 and HEK293/mTLR4-MD-2 lines were estab-
lished by stable transfection of mTLR2 and mMD-2
expression plasmids obtained from H. Heine (Research
Center Borstel, Germany), D. Golenbock (University of
Massachusetts Medical School, USA) and K. Myake
(Institute of Medical Science, Tokyo, Japan). The
mTLR4 coding sequence was reamplified from a
RAW264.7 cDNA library. Peritoneal and bone marrow
derived primary murine macrophages, as well as spleno-
cytes were prepared as described and cultured for analy-
sis without or after challenge with TLR ligands [39].
Macrophages and splenocytes were cultured in 50 μM
Mercaptoethanol, 10% heat inactivated FCS, pen/strep
as antibiotics at standard concentration in an incubator
under regular cell culture conditions.
Adult matched C57BL/6 wild-type and TLR2-/- mice
[40] were used for experiments. The mice experiments
followed internationally recognized guidelines and were
approved by the Government of Upper Bavaria.
2. aT2ib assembly
Total RNA of the hybridoma T2.5 was isolated using the
RNeasy Mini Kit (Qiagen; Hilden, Germany) and the
cDNA synthesized using a “First-strand cDNA synthesis
kit” (GE Healthcare, England). DNA fragments encoding
the variable domains of the heavy and the light chain of
T2.5 were amplified using consensus primer [41], for
the variable domain of the heavy chain VH1Back-1: 5′-
CAG GTS MAR CTG CAG SAG TCW GG (S = G or
C, M = A or C, R = A or G, W = A or T) and
VH1FOR-2: 5′-TGA GGA GAC GGT GAC CGT GGT
CCC TTG GCC CC. The variable domain of the light
chain was amplified applying VK2Back: 5′-GAC ATT
GAG CTC ACC CAG TCT CCA and MJK1FONX: 5′-
CCG TTT GAT TTC CAG CTT GGT GCC. The PCR
products of the heavy chain and light chain were puri-
fied from an 1% agarose gel and directly used for assem-
bly of the variable domain of the heavy and light chain
with a linker sequence that creates a 15 amino acid
sequence (Gly4Ser)3 between both domains. The linker
was generated from the scFv A7 isolated by phage dis-
play [42] by a PCR with the primer LINK BACK: 5′-
GGC ACC ACG GTC ACC GTC TCC TCA and LINK
FOR 5′-TGG AGA CTG AGT GAG CTC GAT GTC.
The assembly PCR was performed in two steps. In the
first reaction equimolar amounts of the DNA of the VH
and VL domain and the synthetic linker were incubated
with 25 pmol of the primer VH1 Back and MJK1FONX
in a PCR of 50 μl containing 1.0 mM dNTPs, 2.5 mM
MgCl2 (Qiagen), 5 μl 10 × PCR buffer (Qiagen) and 1 μl
(1 U) Taq Polymerase (Qiagen). PCR amplification was
performed by incubation for 20 cycles at 94°C for 1.5
min and 65°C for 3 min.
In a second step 25 pmol of the VH1Back primer con-
taining a Sal I restriction site and 25 pmol of the
MJK1FONX primer containing a Not I restriction site was
added and the volume filled up with dNTPs (0.4 mM),
5 μl 10 × PCR buffer, H2O and 1 μl Taq Polymerase (1 U)
to 100 μl. Incubation was performed for 30 cycles at 94°C
for 1 min, 55°C for 2 min and 72°C for 2 min. This results
in a complete scFv intrabody gene.
After purification of the assembled scFv from a 1%
agarose gel the PCR product was cloned into linearised
pCR2.1 vector containing 3’ T overhangs (Invitrogen,
Karlsruhe, Germany). The ligated DNA was transformed
into E. coli Top 10 and after blue-white screening, posi-
tive clones were restricted with Sal I and Not I and
respective inserts ligated into Sal I and Not I cleavage
sites upon dephosphorylation with Shrimp alkaline
phosphatase (USB Corporation, Cleveland, USA) of
pCMV/myc/ER vector (Invitrogen). This vector encodes
an ER signal peptide, contains a multicloning site (Pst I,
Sal I, Xho I, Not I) as well as encodes a myc epitope and
the ER retention signal SEKDEL. After cloning
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sequences encoding both a myc tag and an ER retention
motif were fused 3′-terminally to the preceding anti-
TLR2 scFv fragment. This plasmid drove expression of
the scFv-myc-SEKDEL ER retention signal construct,
which was identical to aT2ib.
3. Construction of an adenoviral vector for aT2ib
transduction, production of recombinant virus, and
infection in vitro and in vivo
Constructing an adenoviral vector carrying a bicystronic
expression cassette driving expression of ER intrabody
aT2ib and the reporter gene EGFP a strategy compris-
ing two cloning steps was pursued. In the first step the
intrabody expression cassette was cloned into the vector
pGEM/IRES/EGFP [43] containing the IRES sequence
of the poliovirus followed by the reporter gene EGFP.
In a second step the bicystronic expression cassette
containing the CMV promotor, the aT2ib coding
sequence, the IRES sequence and the reporter gene
EGFP was ligated into the adenoviral cosmid vector
pAdcos45EGFPC1 [43].
First the plasmid pCMV/myc/ER containing the
anti-TLR2 ER intrabody gene (aT2ib) coding sequence
was linearised using Eco RI. To generate a Sfi I restric-
tion site the linearised vector was ligated with the oli-
gonucleotid LINKER ADENO: 5′-AAT TGC GGC
CGC CAT GGC CGC (Sfi I restriction site is marked
bold). 5 μg of the linker containing the Sfi I restriction
site was ligated with 1 μg of the linearised vector
using 4.5 Units T4 DNA Ligase (Promega, Germany)
overnight at 20°C in a volume of 15 μl. Excess of the
fragment was removed by dialysis of the sample
against 10 mM Tris-HCL, 0.1 mM EDTA and the
ligated DNA was transformed into E. coli DH5a .
From a positive clone (pCMV/myc/ER/aT2ib/Sfi I) the
aT2ib gene with the CMV promoter was cut out by
restriction with Sfi I and Xba I and ligated into
dephosphorylated pGEM/IRES/EGFP restricted with
Sfi I and Avr II. After transformation into E. coli
DH5a positive clones (pGEM/aT2ib/IRES/EGFP/Sfi I)
containing the bycistronic expression cassette of the
aT2ib gene and the reporter gene EGFP were used for
the second step. pGEM/aT2ib/IRES/EGFP/Sfi I was
restricted with Pvu II and Xba I and the bicystronic
expression cassette encompassing the CMV promotor
was ligated into the adenoviral vector pAdcos45
EGFPC1 from which the EGFP gene with the CMV
promoter was removed by restriction with Swa I and
Xba I. The adenoviral vector pAdcos45 EGFPC1 con-
tains the genome of a replication deficient adenovirus
type 5 subgenus C in which the E1 and E3 region is
deleted [43]. The adenoviral vector contains the repor-
ter gene EGFP. Its expression is driven by the immedi-
ate early CMV promoter.
After ligation the adenoviral cosmid DNA was pack-
aged in vitro and transduced into E. coli. Two indepen-
dent cosmid clones, namely AdVaT2ib/3 and
AdVaT2ib/7 comprising identical sequences, were used
for the generation of recombinant adenovirus. For pro-
duction of AdVaT2ib particles HEK293 cells were trans-
fected with 10 μg cosmid DNA in 80cm2cell culture
flasks grown to 60% - 80% confluence. After 7-14 days
viral plaques were visible. The recombinant adenovirus
was propagated as described [44] and purified by CsCl
gradient ultracentrifugation. For infection with the
recombinant adenovirus RAW264.7 and primary perito-
neal macrophages were cultured until 80% confluence
was reached. Infection was carried out at a multiplicity
of infection (moi) of 10 for the control virus AdVGFP
which overexpressed EGFP but not an additional protein
and at a moi of 100 for AdVaT2ib with infection buffer
(PBS containing 2% FCS) for 1 h at room temperature
since it resulted in equal EGFP expression levels. After
infection MEM containing 5% FCS was added and the
cells were incubated for 1 day to 3 days after which
expression of the reporter EGFP was analysed by mea-
surement of immunofluorescence and flow cytometry.
Mice were infected by intravenous (i. v.) or intraperi-
toneal (i. p.) injection of 1 × 109 plaque forming units
(pfu) of AdVaT2ib or control virus (AdVGFP) and ana-
lysed 6 days thereafter upon removal of cells by assaying
ex vivo/invitro using ELISA.
4. Immunoblot and immunofluorescence analysis
Transiently intrabody expression plasmid transfected
HEK293 cells and with recombinant adenovirus trans-
duced RAW264.7 macrophages were lysed by incuba-
tion in lysis buffer (150 mM NaCl, 20 mM Tris/HCl
pH7.4, 1% Triton-X-100, 10 mM EDTA, 100 μM vana-
date, 1% Trasylol, 1 mM PMSF, 1 mM zinc acetate)
for 20 min on ice. Lysates were centrifuged for 15 min
in a table top centrifuge and a supernatant aliquot
representing 5 × 105 cells was loaded on a lane of a
PAA gel (12.5%) for subsequent SDS-PAGE. After
blotting the membrane was blocked in 2.5% skimmed
milk in PBS containing 0.05% Tween 20 at room tem-
perature for 1 h. The intrabody band was visualized by
using a mouse anti-myc antibody (Santa Cruz Biotech-
nology, Heidelberg, Germany) and a goat anti-mouse
IgG Fcg antibody coupled with horseradish peroxidase
(Dianova, Hamburg, Germany). The blot was devel-
oped using 3,3′-diaminobenzidine tetrahydrochloride
(DAB) liquid substrate (Sigma, Deisenhofen, Germany).
For immunofluorescence based expression assay by
microscopy or FACS the reporter gene product EGFP
was visualized using UV light and a FITC filter. For
analysis of intrabody expression cells were fixed with
3.7% formaldehyde (15 min at room temperature),
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washed 3 times with PBS and further permeabilized
with 0.1% Triton X-100 for 10 min. After washing with
PBS for 5 times, cells were blocked with PBS contain-
ing 3% BSA for 1 h at room temperature. Antibody
incubation was performed with mouse anti-myc anti-
body and a TRITC labeled goat anti-mouse IgG anti-
body (Dianova).
5. NF-B dependent luciferase assay in HEK293 cells
overexpressing both specific TLRs and aT2ib
3 × 104 human embryonic kidney (HEK293) fibroblas-
toid cells were seeded per well of a 96-well cell culture
plate and transfected with plasmids directing constitu-
tive expression of mTLR2 or other TLRs, aT2ib or con-
trol intrabody (anti-VEGFR 2 intrabody scFv A7, aVR-
ib [45], and Renilla luciferase, as well as NF-B depen-
dent expression of firefly luciferase. After 24 h cells
were challenged with TLR agonists E. coli O111:B4 LPS
(Sigma), tripalmitoylated hexapeptide (Pam3CSK4, EMC
microcollections), poly I:C (Sigma), or oligodeoxynucleo-
tide (1668, TIB Molbiol) for additional 16 h and lysed
subsequently for analysis of luciferase activity.
6. Subcellular colocalisation and co-immunoprecipitation
of aT2ib and mouse/human TLR2
For colocalisation HEK293 cells overexpressing mouse
TLR2 were grown on sterile coverslips and transiently
transfected with aT2ib expression plasmid. The cells
were washed once with PBS-0.05% Tween 20, fixed for
10 minutes with 4% formaldehyd followed by permea-
bilisation of the cells with 0.1% Triton X-100 for
10 min at room temperature. After blocking with 3%
BSA triple staining of aT2ib, mouse TLR2 and Cal-
nexin was performed with polyclonal anti-mouse TLR2
serum [46], anti-calnexin antibody (Abcam, Cambridge,
UK, clone AF18) and subsequent incubation with a
FITC labelled goat anti-myc antibody, Cy3 labelled
goat anti-mouse antibody (Dianova) and Cy5 labelled
goat anti-rabbit antibody (Dianova). Incubation of anti-
bodies was performed over a period of 1 h at room
temperatur. Between incubation steps cells were
washed 3 times with PBS-0.05% Tween 20. The cover-
slips were embedded in Moviol (Merk, Darmstadt,
Germany) and analysed with a laser scanning confocal
microscope (LSM 510 META, Carl Zeiss). Co-
immunoprecipitation was performed as described
before [46]. Briefly, each partner of protein pairs to be
analysed for their potential to interact in a cellular
context were overexpressed as fusion proteins in HEK
293 cells upon transfection by Ca3(PO4)2-DNA precipi-
tation. Specifically, human TLR2 was coupled to an N-
terminal Flag-tag while intrabody constructs contained
C-terminal myc-tags (see Fig. 1a exemplarily). Subse-
quently, cells were lysed (0.5% NP40, 150 mM NaCl
and further ingredients [46]) upon which nuclei were
removed by centrifugation. Myc-specific antibody
(Sigma) and protein G beads (Santa Cruz) were added
synchronously and lysates incubated on a roller at 4°C
for 16 h. Upon 5 washes with lysis buffer sample buffer
was added and samples were subjected to SDS-PAGE
and analysed upon blotting using tag-specific anti-
bodies (Sigma).
7. Analysis of TLR2 and TLR4 cell surface expression of
transfected HEK293 cells and macrophages
aT2ib expression plasmid transfected HEK293 cells
overexpressing mTLR2, as well as AdVaT2ib infected
RAW264.7 and primary macrophages derived from bone
marrow were stained with murine/human TLR2 specific
T2.5 or mTLR4 specific UT41 to determine surface
expression of specific TLRs by flow cytometry. Staining
with antibodies was performed for 30 min at 4°C in a
96-well microtitre plate (Nunclon™ Surface plate, Nunc)
in 100 μl PBS containing 2% FCS (Invitrogen) using a
phycoerythrin-labelled anti-mouse TLR2 antibody (clone
T2.5, HBT) or a phycoerythrin-labelled anti-mTLR4
antibody (clone UT41, HBT). As isotype control a phy-
coerythrin labelled mouse IgG1 (clone P3, HBT) was
used. Cells were washed once with PBS containing 2%
FCS and resuspended in 300 μl PBS containing 2% FCS
and 10 μg/ml propidiumiodide for subsequent analysis
using a FACS Calibur™ (Becton Dickinson).
8. Analysis of intracellular TNFa by flow cytometry
2 × 106 RAW267.4 macrophages in one well of a 6-well
microtitre plate (uninfected, infected with AdVGFP or
AdVaT2ib) in 1 ml medium were stimulated with 100
ng/ml tripalmitoylated hexapeptide Pam3CSK4 (EMC
microcollections) or 100 ng/ml LPS (Alexis) for 4 h at
room temperature. Fixation, permeabilization, and intra-
cellular TNFa transport inhibition were performed
using cytofix/cytoperm™ plus fixation/permeabilization
and golgiplug™ protein transport inhibitor (BD Bios-
ciences Pharmingen). Challenge with TLR agonists was
performed in the presence of 1 μl golgi stop ™ solution
in 1 ml medium. Cells were washed once with PBS
containing 2% FCS and resuspended in 250 μl fixation/
permeabilization solution and incubated for 20 min at
4°C. After washing the pellet once with Perm/Wash™
buffer Fcg-receptors were blocked by incubation with
anti-CD16/CD32 antibodies (BD Bioscience Pharmin-
gen) for 30 min at 4°C. The cells were washed and
stained intracellularly as described above for cell surface
staining. Antibodies used were a phycoerythrin-labelled
hamster anti-mouse/rat TNFa antibody (clone TN3-
19.12) and isotype control phycoerythrin-labelled ham-
ster IgG1 antibody (clone G235-2356, both BD Bios-
ciences, Pharmingen).
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9. Analysis of TNFa and IL-6 mRNA accumulation by
reverse transcription (RT) and subsequent PCR mediated
amplification
After cellular challenge with 100 ng/ml Pam3CSK4 or
100 ng/ml LPS for 4 h cellular RNA was isolated
(RNeasy, Qiagen) and cDNA synthesized using 1 μg
RNA and a random hexamer primer according to sup-
plier instructions (GE Healthcare). Amplification of
murine TNFa and IL-6 mRNA was performed by PCR
using the following primers: TNFa reverse: 5′-ATGAG-
CACAGAAAGCATGATC and TNFa forward: 5′-
CACAGAGCAATGACTCCAAAG, as well as IL-6
reverse: 5′-ATGAAGTTCCTCTCTGCAAGA and IL-6
forward: 5′-GGTTTGCCGAGTAGATCTCAA. The
PCR was carried out in 20 μl of PCR buffer (1 mMTris-
Cl, 10 mM KCL, 2 mM (NH4)2SO4, 35 mM MgCl2, pH
8.0), 2.5 mM dNTPs, 0.5 U of Taq DNA polymerase
(Qiagen) and 10 pmol primers (Operon). Hypoxanthine-
guanine phosphoribosyl transferase (HPRT) mRNA was
amplified as control (HPRT reverse: 5′-TCAACGGGG-
GACATAAAA, HPRT forward: 5′-ATTCAACTTGCGC
TCATCTT).
10. ELISA
TNFa and IL-6 concentrations in supernatants were
analysed by application of ELISA kits according to sup-
plier instructions (BD Biosciences). Aside of other TLR
ligands (see above), a TLR7 specific compound (R848,
Alexis) was applied to primary cells.
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